{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:35:55Z","timestamp":1714019755284},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Perinatal transmission of hepatitis B virus continues to be a serious global public health concern. Transmission failures are related to high maternal viremia. Several antiviral therapies reduce maternal viremia around the time of delivery and decrease maternal-to-child-transmission. This chapter is a review of current studies that, ultimately, have provided strong evidence for the efficacy and safety of 3 antiviral drugs in pregnancy\u2014lamivudine, telbivudine and tenofovir. The latter drug is the particular focus of this chapter which will show that tenofovir is the preferred antiviral therapy in pregnant women because of its potency, safety profile, and low risk of resistance.<\/jats:p>","DOI":"10.1097\/grf.0000000000000438","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T20:17:45Z","timestamp":1553890665000},"page":"835-845","source":"Crossref","is-referenced-by-count":1,"title":["Evidence for Use of Tenofovir in Pregnancy to Prevent Perinatal Transmission of Hepatitis B Infection"],"prefix":"10.1097","volume":"62","author":[{"given":"KENDRA R.","family":"SYLVESTER-ARMSTRONG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PATRICK","family":"DUFF","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1126\/science.325649","article-title":"Australia antigen and the biology of hepatitis B","volume":"197","author":"Blumberg","year":"1977","journal-title":"Science"},{"key":"R3-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices","volume":"67","author":"Schille","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajog.2015.09.100","article-title":"Hepatitis B in pregnancy screening, treatment and prevention of vertical transmission","volume":"214","author":"Dionne-Odom","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0264-410X(97)00080-7","article-title":"Ten year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long term immunogenicity","volume":"15","author":"Del Canho","year":"1997","journal-title":"Vaccine"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2014.08.043","article-title":"Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long term study","volume":"13","author":"Quanxin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","article-title":"Antiviral therapy in chronic hepatitis B virus infection during pregnancy: a systematic review and meta-analysis","volume":"63","author":"Brown","year":"2016","journal-title":"Hepatology"},{"key":"R10-20230911","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2893.2008.01056.x","article-title":"Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicenter, randomized, double blind, placebo controlled study","volume":"16","author":"Xu","year":"2009","journal-title":"J Viral Hepat"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.3748\/wjg.v17.i38.4321","article-title":"A meta-analysis of lamivudine for interruption of mother-to child transmission of hepatitis B virus","volume":"17","author":"Han","year":"2011","journal-title":"World J Gastroenterol"},{"issue":"suppl","key":"R12-20230911","doi-asserted-by":"crossref","first-page":"S174","DOI":"10.1002\/hep.22900","article-title":"Antiviral resistance and hepatitis B therapy","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R14-20230911","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.cgh.2014.08.043","article-title":"Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads: a prospective long term study","volume":"13","author":"Wu","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jvh.12834","article-title":"Safety and efficacy of telbivudine in late pregnancy to prevent mother-to-child transmission of hepatitis B virus: a multicenter prospective cohort study","volume":"24","author":"Hu","year":"2018","journal-title":"J Vial Hepat"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1743-422X-7-211","article-title":"Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review","volume":"7","author":"Zhao","year":"2010","journal-title":"Virol J"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenoforvir disoproxil fumerate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1517\/14728214.12.2.199","article-title":"Emerging drugs for hepatitis B","volume":"12","author":"Zoulim","year":"2007","journal-title":"Expert Opin Emerg Drugs"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to prevent hepatitis B transmission in mothers with high viral load","volume":"374","author":"Pan","year":"2016","journal-title":"N Engl J Med"},{"key":"R21-20230911","first-page":"18","article-title":"Tenofovir treatment in pregnant women with HBV reduces vertical transmission","volume":"29","author":"Jackson","year":"2017","journal-title":"OBG Management"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/apt.14068","article-title":"Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus","volume":"45","author":"Hyun","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus placebo to prevent transmission of hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N Engl J Med"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.26686","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos","year":"2014","journal-title":"Hepatology"},{"key":"R25-20230911","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3748\/wjg.v24.i17.1919","article-title":"Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-na\u00efve chronic hepatitis B: a case report and review of the literature","volume":"24","author":"Cho","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R26-20230911","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/cid\/civ437","article-title":"Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumerate during pregnancy","volume":"61","author":"Siberry","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R27-20230911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","article-title":"Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis","volume":"76","author":"Nachega","year":"2017","journal-title":"Acquir Immune Defic Syndr"},{"key":"R29-20230911","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00514-10","article-title":"Concentrations of tenofovir and emtricitabine in breast milk of HIV-1 infected women in Abidjan, Cote d\u2019loire, in the ANRS 120109 TEmAA Study, Step 2","volume":"55","author":"Benaboud","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"R30-20230911","first-page":"9","article-title":"Tenofovir exposure through breastfeeding: serum concentrations in neonates and clinical follow-up","volume":"26","author":"Gourad","year":"2012","journal-title":"Fundam Clinic Pharmacol"},{"key":"R31-20230911"},{"key":"R32-20230911","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6728a2","article-title":"Access to treatment for hepatitis B virus infection\u2014worldwide, 2016","volume":"67","author":"Hutin","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R33-20230911","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/apt.12726","article-title":"Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against postpartum flare","volume":"39","author":"Nguyen","year":"2014","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:17:31Z","timestamp":1694420251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/GRF.0000000000000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000438","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}